Merck acquisition of OncoImmune: A strategic move to strengthen COVID-19 treatment pipeline
In a significant acquisition aimed at enhancing its COVID-19 therapeutic offerings, pharmaceutical giant Merck has entered into an all-cash deal valued at $425 million to ... Read More
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the acquisition of VelosBio, a clinical-stage biopharmaceutical company ... Read More
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More
Merck to acquire coronavirus vaccine candidate developer Themis Bioscience
Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an ... Read More
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the ... Read More
Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, ... Read More
Merck secures EC approval for Keytruda in combination therapy for lung cancer
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination ... Read More